Company Media Media 2024

2024

The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!

26 April 2024

CEO Steve Lydeamore provides an update on Travelan's exponential growth!

Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com

10 April 2024

Immuron Ltd (NASDAQ:IMRN, ASX:IMC), a biopharmaceutical company headquartered in Australia, says sales of its immune supplement Travelan® have soared.

Guarding Gut Health on the Go: The Travelan® Advantage

10 April 2024

The Not Old Better Show, Art of Living Interview Series. Today's episode takes us on a fascinating journey through the landscape of travel health, an essential yet often overlooked aspect of our adventures abroad.

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Filter Categories

2024

The Watchlist: Immuron's Travelan sales growth, clinical pipeline achievements and upcoming milestones!

Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com

Guarding Gut Health on the Go: The Travelan® Advantage

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information